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Abstract 
Objectives: In this study, we investigated whether single nucleotide polymorphisms (SNPs) in 
folylpoly--glutamate synthase (FPGS), which catalyzes the polyglutamation of pemetrexed (PEM), 
is related to FPGS expression and the response to PEM in non-small cell lung cancer (NSCLC). 
Materials and Methods: We first examined FPGS protein expressions according to FPGS SNPs 
genotype groups in 15 lung adenocarcinoma cell lines. Next, 101 non-squamous NSCLC patients 
treated with PEM and platinum drugs were classified into FPGS SNP genotype groups to investigate 
the relation between FPGS SNP genotypes and treatment outcome. 
Results: When the 15 adenocarcinoma cell lines were classified into FPGS SNP 2572C>T genotype 
groups, we found that the FPGS protein expression was significantly higher in the CC genotype 
group than in the TT+CT genotype group (p = 0.0022). In contrast, there was no significant 
difference in FPGS expression when another FPGS SNP was analyzed. We also examined the FPGS 
SNP 2572C>T genotype in 101 non-squamous NSCLC patients treated with PEM and platinum 
drugs. Among these 101 patients, response rate was significantly higher in the CC genotype group 
than in the TT+CT genotype group (p = 0.0034). When we examined the patients treated with PEM, 
platinum drugs and Bev, almost all (29/33) were classified into the TT+CT genotype group. The 
response rate, progression-free survival, and over-all survival were all significantly better in the 
patients of the TT+CT genotype group who also received Bev than in those who did not receive Bev 
(p = 0.034, 0.021, 0.018, respectively). 
Conclusion: FPGS SNP 2572C>T is a predictive marker of the efficacy of PEM and platinum drugs 
for NSCLC. 
 
